No. A prescription bearing a patient’s name is not, by itself, a sufficient significant-difference determination under FDA’s 503A copying guidance. The guidance describes a change producing a significant difference for the identified patient, as determined by the prescriber, and recommends documenting that determination. (fda.gov)
Ask the medical director and counsel to review:
- The approved comparator.
- The actual formulation change.
- The patient-specific reason for that change.
- The prescriber’s independent determination.
- How the pharmacy receives and retains the documentation.
- Whether the other applicable compounding conditions are satisfied.
Do not ask procurement staff to generate clinical justifications, and do not treat a supplier’s pre-filled rationale as evidence of an independent prescribing decision.
FDA’s guidance also states that lower price does not establish the required formulation-related difference. Affordability should be addressed through the access comparison, not presented as an automatic copying exception. (fda.gov)
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf